For instance, inducing the expression of SIGIRR in CD4-positive T cells for the treatment of SLE, allergic rhinitis and asthma, or in endothelial cells for the management of KD and related intestinal disorders, or hepatocytes for hepatitis could potentially serve as a promising drug target to moderately inhibit the inappropriate inflammatory response. Here, SIGIRR is linked to hepatitis A virus infection.